This HTML5 document contains 99 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dcthttp://purl.org/dc/terms/
dbpedia-shhttp://sh.dbpedia.org/resource/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n16https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n4http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
dbpedia-srhttp://sr.dbpedia.org/resource/
n11http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Saroglitazar
rdf:type
n4:ChemicalObject yago:WikicatMolecularFormulas yago:MolecularFormula106817173 dbo:ChemicalSubstance yago:Statement106722453 yago:Compound114818238 yago:Matter100020827 yago:PhysicalEntity100001930 yago:WikicatCarboxylicAcids yago:Abstraction100002137 yago:Formula106816935 dbo:Drug yago:CarboxylicAcid114739360 yago:Message106598915 yago:Part113809207 yago:Substance100019613 yago:Relation100031921 wikidata:Q8386 owl:Thing yago:Material114580897 yago:Chemical114806838 yago:Acid114607521 yago:Communication100033020
rdfs:label
Saroglitazar
rdfs:comment
Saroglitazar (INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.
foaf:depiction
n11:Saroglitazar_skeletal.svg
dct:subject
dbc:Carboxylic_acids dbc:PPAR_agonists
dbo:wikiPageID
39596242
dbo:wikiPageRevisionID
1122994566
dbo:wikiPageWikiLink
dbr:HDL_cholesterol dbr:Dyslipidemia dbr:Retinopathy dbr:Insulin_sensitizer dbr:PPARα dbr:PPARγ dbr:Cholesterol dbr:Statin dbr:Insulin_resistance dbr:International_Nonproprietary_Name dbr:Triglycerides dbr:Peroxisome_proliferator-activated_receptor dbr:PPAR_agonist dbr:Diabetic_nephropathy dbr:Type_2_diabetes_mellitus dbc:Carboxylic_acids dbr:Drug_Controller_General_of_India dbr:HbA1c dbc:PPAR_agonists dbr:Anti-diabetic_medication dbr:Hypertriglyceridemia
owl:sameAs
dbpedia-sh:Saroglitazar n16:XApf yago-res:Saroglitazar dbpedia-sr:Saroglitazar wikidata:Q15269693 freebase:m.0vxfc39
dbp:wikiPageUsesTemplate
dbt:Reflist dbt:Oral_hypoglycemics_and_insulin_analogs dbt:Short_description dbt:Fdacite dbt:PPAR_modulators dbt:Drugbox
dbo:thumbnail
n11:Saroglitazar_skeletal.svg?width=300
dbp:atcPrefix
None
dbp:c
25
dbp:casNumber
495399
dbp:chebi
134708
dbp:chemspiderid
32079086
dbp:h
29
dbp:iupacName
-2
dbp:legalStatus
Approved in India
dbp:n
1
dbp:o
4
dbp:pregnancyCategory
C
dbp:pubchem
60151560
dbp:routesOfAdministration
Oral
dbp:s
1
dbp:smiles
CSc3ccc-cn1CCOcccc2CCOCC
dbp:stdinchi
1
dbp:stdinchikey
MRWFZSLZNUJVQW-DEOSSOPVSA-N
dbp:tradename
Lipaglyn
dbp:unii
E0YMX3S4JD
dbo:abstract
Saroglitazar (INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.
gold:hypernym
dbr:Drug
prov:wasDerivedFrom
wikipedia-en:Saroglitazar?oldid=1122994566&ns=0
dbo:wikiPageLength
6274
dbo:alternativeName
Lipaglyn
dbo:casNumber
495399-09-2
dbo:chEBI
134708
dbo:fdaUniiCode
E0YMX3S4JD
dbo:pubchem
60151560
foaf:isPrimaryTopicOf
wikipedia-en:Saroglitazar
Subject Item
dbr:PPAR_agonist
dbo:wikiPageWikiLink
dbr:Saroglitazar
Subject Item
dbr:C25H29NO4S
dbo:wikiPageWikiLink
dbr:Saroglitazar
dbo:wikiPageRedirects
dbr:Saroglitazar
Subject Item
dbr:Lipaglyn
dbo:wikiPageWikiLink
dbr:Saroglitazar
dbo:wikiPageRedirects
dbr:Saroglitazar
Subject Item
wikipedia-en:Saroglitazar
foaf:primaryTopic
dbr:Saroglitazar